Post-earnings recap
Reported
Thu, Aug 9, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss per share of $0.59, but the stock still rose by 0.99% following the earnings announcement. Investors may be optimistic about the company's ongoing research and development efforts, despite the lack of specific revenue figures or guidance. The positive stock reaction suggests that the market is focusing on long-term potential rather than short-term earnings.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to developing innovative treatments. There was no specific guidance or revenue expectations shared.
Management did not provide specific revenue figures or future guidance during the call.
The focus remains on advancing their pipeline of therapies.